RG6182 / Roche - LARVOL DELTA

Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Hoffmann-La Roche

Trial initiation date • CNS Disorders • Multiple Sclerosis

Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Hoffmann-La Roche | N=235 ➔ 360

Enrollment change • Trial initiation date • CNS Disorders • Multiple Sclerosis

Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Hoffmann-La Roche

Trial initiation date • CNS Disorders • Multiple Sclerosis

BP46016: A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has progressed (clinicaltrialsregister.eu) - P1/2 | N=220 | Recruiting | Sponsor: F. Hoffmann-La Roche AG

New P1/2 trial • CNS Disorders • Multiple Sclerosis

Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis